The positive effect of renin-angiotensin-aldosterone system (RAAS) blockade and sodium-glucose co-transporter 2 (SGLT2) inhibitors on renal hemodynamics in patients with HTN and T2DM has been previously described (22, 23). This evidence concerns the gene SLC5A2 and hypertensive disorder.